Background To assess the structure of individual-level needle and syringe coverage measurement formula, and to estimate the impact of coverage-related behaviours/parameters (instances of syringe acquisition, total syringes acquired, peer-to-peer syringe distribution, injecting frequency) on overall coverage.
Introduction
Needle and syringe program (NSP) coverage can be defined as the number of sterile needles and syringes (hereafter, 'syringe/s') acquired by people who inject drugs (PWID) relative to their injecting frequency. Multiple methods have been devised to estimate coverage according to this definition, the most prominent being Bluthenthal et al.'s measure. 1 Individuallevel coverage measurements recognize that PWID have disparate injecting risk, while population-level measures assume homogeneity. For example, the WHO recommendation to distribute 200 syringes per PWID per annum 2 is inappropriate for PWID injecting at higher frequencies.
The coverage calculation formula includes several parameters, each corresponding to a particular PWID practice.
Previous coverage measures have included instances of syringe acquisition, 1, 3, 4 peer-to-peer distribution [4] [5] [6] and stockpiling; 6 however, these parameters only supplement the central parameters of coverage: total syringes acquired and injecting frequency.
Bluthenthal et al. 1 showed that as individual-level coverage levels increased, the odds of reporting injecting risk behaviour decreased. This pattern continued even after coverage became sufficient (defined as 100% of injecting episodes covered by at least one sterile syringe), suggesting that having more syringes than actually required can further reduce risky injecting practices, illustrating the complex relationship between coverage, the behaviours that constitute its calculation, and injecting risk.
Whilst the research cited above tested associations between coverage as a categorical variable and various exposures, the effect each parameter has upon coverage as a continuous measure is uncertain. Whether change in syringe acquisition affects coverage more than (e.g.) change in injecting frequency is unknown. The effects of syringe access on injecting risk 7 and dispensation policy 8 on coverage have been well studied previously, but it remains uncertain which individual-level behavior is the more dominant driver of coverage. A nuanced understanding of these impacts is needed to improve coverage for PWID populations.
Finally, individual-level coverage has not been measured consistently, impairing the comparability of research. For example, O'Keefe et al. 5 and McCormack et al. 6 measured coverage by recording explicit responses to each parameter for a specified time period, whilst Bluthenthal et al.
1 extrapolated coverage by multiplying the number of syringes retained at the last instance of syringe acquisition by the number of syringe acquisitions per participant within 30 days. Differing methodologies have differing biases and weaknesses, highlighting the value of an exploration of measurement construction and optimal format.
In this article, we use data from a cohort of PWID in Melbourne, Australia, to analyse the change in each coverage parameter over time and their effect on coverage levels. Specifically, we:
(1) describe the longitudinal changes to individual-level coverage and determine correlations between parameters, (2) compare the effect of change in each coverage parameter upon coverage as a continuous measure, and (3) assess the appropriateness of parameters' inclusion in coverage formulae.
Methods

Data source
Our data are drawn from the Melbourne injecting drug user cohort study (MIX), described in detail elsewhere. 9 The 757 participants include those from the original MIX recruitment phase of 688 participants in 2008-10, and 69 participants from the Networks II cohort, 10 enroled in 2011. Both MIX and Networks II sought to recruit regular PWID. The cohorts' baseline characteristics are comparable.
11
Eligibility criteria for the original MIX cohort were age 18-30 years and reporting injecting of heroin and/or methamphetamine regularly (at least monthly in the 6 months before recruitment). Informed written consent was obtained. The Victorian Department of Health Human Research Ethics Committee and the Monash University Human Research Ethics Committee approved the study.
Participant sample
At May 2016, MIX included 3312 interviews over nine interview waves. We used data after the introduction of coverage questions in June 2010 (excluding 902 interviews, and 176 participants). Due to our longitudinal focus, we also excluded 63 participants with only one interview after June 2010. The final dataset had 518 participants and 2347 interviews over a maximum of seven separate interview waves. Attrition was low, with 88% of included participants completing at least three interviews.
Coverage parameters
We compared four parameters for the 2 weeks prior to interview: instances of syringe acquisition (number of acquisitions of sterile syringes from any source), total syringes acquired, peer-to-peer syringe distribution and injecting frequency. Parameters came from the following questions:
'How many times in the last 2 weeks did you get (needles and) syringes?' 'In the last 2 weeks how many new (needles and) syringes in total did you get?' 'In the last 2 weeks how many new (needles and) syringes did you give away or sell to others?' Past week injecting frequencies for 18 drug types were summed to create a total injecting frequency variable. To create an equitable timeframe for coverage calculation, past week injecting frequency was doubled to match the timeframe specified in the other coverage parameters. Injecting frequency was multiplied rather than total syringes acquired being divided because injecting frequency was less variable, suggesting more consistent practice.
Calculating coverage
We adapted Bluthenthal et al.'s 1 method to calculate individual-level syringe coverage. Our method utilizes only syringes acquired, syringe distribution and injecting frequency parameters. Syringes distributed is subtracted from total syringes acquired, divided by the past 2-week estimate of injecting frequency, and multiplied by 100, giving a percentage of injecting episodes covered by a sterile syringe. The coverage formula is as follows:
Coverage was only calculated for participants with valid data for each coverage parameter and who reported both syringe acquisition and injecting within the 2-week period (as no injecting precluded coverage calculation, whilst injecting without syringe acquisition was plausibly influenced by syringe stockpiling-see Limitations). Overall, 44% of coverage responses (1029 observations) were missing, most (735 observations, 71% of all missing responses) due to injecting abstinence. Another 262 coverage observations were missing due to no syringe acquisition by participants who reported injecting (25% of all missing responses). The remaining 4% of missing coverage responses were due to missing/invalid data in any of the coverage variables.
Calculating coverage change
To calculate longitudinal change in coverage and coverage parameters, the reported values of continuous coverage and each coverage parameter were subtracted from the same variable at the next immediately preceding, non-missing longitudinal observation.
To avoid the influence of stockpiling, each parameter change variable was classified as 'missing' if the participant reported 'zero' injecting at the succeeding interview and if there was zero change in the parameter change variable.
Treatment of outliers
We inspected the data for each change variable and noted extreme outliers that influenced the overall distributions. Several outlier treatments were tested using quantiles of normal distribution plots, whilst seeking to maximize data inclusion.
For each change variable we tested the following exclusion methods: exclusion of all values ±2 standard deviations from the mean; all data at the extreme 5% of either end of the distribution (10% of the overall distribution); all data at the extreme 2.5% of the distribution (5% overall); and the extreme 1% of the distribution (2% overall). The 2.5% method of exclusion accounted for outlier influence without excluding too many data points: 71 observations for 'change in total syringes acquired', 67 for 'change in syringe distribution', 73 for 'change in instances of syringe acquisition', 61 for 'change in injecting frequency' and 34 for the 'change in continuous coverage' variable.
Statistical analysis
The relationship between changes in the four coverage parameters was tested using Pearson's correlation. The relationship between change in continuous coverage as an outcome and change in the four coverage parameters was estimated using pooled multiple linear regression. To account for repeated measures bias, standard errors were clustered on individual participants.
Factor analysis assesses the correlational relationship between selected continuous variables and potential latent dimensions, or 'factors'. 12 It attempts to identify a common, hypothetical variable/s upon which the analysed variables are weighted, and assesses the strength of each weighting upon the factors. We used exploratory factor analysis to assess the weightings of each coverage parameter on four potential factors, using the raw coverage variables (those included in the coverage formula) as opposed to the transformed 'change' variables. We utilized promax rotation, due to the parameters being correlated, and report factor loadings for each variable.
All analysis was performed in STATA13 (StataCorp. 2013. College Station, TX).
Results
Demographics
At first interview, the amended sample was predominantly male (64%), Australian-born (81%), non-Indigenous (95%), unemployed (78%) and living in stable accommodation (85%). Average age was 30 years, and those reporting injecting (n = 429) mainly injected heroin in the month before interview (73%), followed by methamphetamine (11%).
Change in coverage and coverage parameters
Median continuous coverage values at first and most recent interview were 162% (IQR: 88-350%) and 158% (IQR: 83-321%), respectively. Though coverage as an aggregate continuous outcome was sufficient, when dichotomized, 27 and 26% of the sample were insufficiently covered at their first and most recent interview, respectively.
In the 2 weeks before interview, participants who reported injecting collected a median 15 syringes (IQR: 5-70), distributed a median of zero syringes (IQR: 0-10), collected syringes from any sources a median of one time (IQR: 1-3) and reported a median of five injections (IQR: 2-12).
13 Table 1 presents the mean and range of the change in tested variables between the first and the second interview and between the second-last and the last interview.
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Relationship between parameter change and coverage
The four coverage change parameters were low to moderately correlated. Of the seven tested relationships (Fig. 1) , change in total syringes acquired and change in syringe distribution had the strongest correlation (0.497), followed by change in total syringes acquired and change in injecting frequency (0.302).
The pooled multiple linear regression model showed that the increase in 2-week injecting frequency was associated with the largest effect on continuous coverage change, reducing coverage by 10.93 percentage points for every additional injecting episode between interviews (Table 2 ). Unit increases in syringe distribution and instances of syringe acquisition were associated with reductions in coverage of 5.34 and 5.77 percentage points, respectively (although the association with syringe acquisition was not significant). Only an increase in syringes acquired was associated with increased continuous coverage (a unit increase in total syringes acquired predicting a 5.99 percentage point increase in coverage).
Factor analysis
The factor analysis included 2299 observations. From a potential four-factor solution, positive eigenvalues existed for only the first two factors (factor 1: 1.4552 and factor 2: 0.0059), meaning only these two factors were considered. Before and after promax rotation, all tested parameters loaded most strongly upon factor 1 ( Table 3 -presenting results after rotation), suggesting that all parameters correlate with a common dimension. 'Total syringes acquired' and 'syringe distribution' had the strongest factor loading, whilst 'instances of syringe acquisition' had the weakest.
Discussion
Main findings of this study
In this study, we explored the dynamics of individual-level coverage parameters by assessing their relationships with one another and upon coverage as a continuous outcome.
The correlations between the four change parameters were weak to moderate. Only two pairs showed any real strength of (positive) association: change in total syringes acquired and change in syringe distribution, and change in total syringes acquired and change in injecting frequency.
Multiple linear regression showed that only an increase in total syringes acquired was associated with increased overall coverage, further validating Australia's mostly unlimited syringe dispensation policies, in contrast to more restrictive policies elsewhere. 8 Increases in all other parameters were associated with decreases in coverage.
Factor analysis suggested that the four parameters loaded most strongly upon a single factor, presumably the latent dimension of 'coverage'.
What is already known on this topic
Daily or more injecting frequencies and inconsistent or nonuse of NSPs 1,3,5 have previously been associated with insufficient coverage in regression analysis. 3, 5 and the behaviours that constitute the coverage parameters have previously been explored in isolation in relation to coverage. Bluthenthal et al. 1 found evidence that PWID who have more instances of syringe acquisition, who acquire fewer syringes, who do not distribute syringes and who have higher injecting frequencies have lower coverage levels. However, these studies did not investigate the correlations between individual coverage parameters, or their relative importance in predicting a change in coverage over time.
What this study adds
The correlation between syringe distribution and total syringes acquired suggests that many PWID are purposely acquiring additional syringes to distribute to peers, and is consistent with previous findings that PWID acquire syringes for others, such as friends and family members.
14 Whilst it may be concerning that increased injecting frequency and syringe acquisition are not more strongly correlated, many participants had more than sufficient coverage. Strike et al. 15 categorized PWID by syringe acquisition habits: those stockpiling syringes for personal and others' use; those routinely keeping several days' supply available; and those obtaining syringes only when about to inject. It may be that our PWID stockpiled syringes to cover any increase in injecting frequency.
Our regression results show that as PWID distribute syringes, their reserves diminish, thereby reducing overall coverage. This does not necessarily represent risk, if the distributing individuals account for it in their acquisition. We explored this risk by recalculating the coverage formula. With the peer-to-peer distribution parameter included, 26% of participants were insufficiently covered (<100% coverage); after excluding it, 19% were insufficiently covered, suggesting some PWID do not account for distribution in their syringe acquisition. Peer-to-peer syringe distribution has been characterized as an important adjunct to formalized services, with 32-40% of PWID reporting it.
14 The non-use of NSPs has also been associated with insufficient coverage;
5 peer-to-peer distribution can increase coverage for PWID who eschew formal services, but it is important that this does not decrease the coverage of those distributing.
Increasing instances of syringe acquisition decreased coverage. This finding may appear counterintuitive, and is at odds with Bluthenthal et al.'s 1 findings, but is probably explained by differences between Australia's syringe dispensation policy and the relatively restrictive policies in the United States. At most recent interview, 56% of injectors acquired syringes on one or two occasions over the preceding 2 weeks, but as syringe acquisitions increased, median injecting frequency increased only marginally, suggesting many participants were acquiring syringes for immediate use. Strike et al. 15 showed that such PWID were at greater injecting risk than those who plan acquisition; plausibly, they are at greater risk of reduced coverage.
The associations between the two central parameters (total syringes acquired and injecting frequency) and coverage best indicate how to maximize coverage at the individual level. A one unit increase in injecting frequency was associated with a 10.93 percentage point decrease in continuous coverage, an effect size nearly double that of any other parameter. This effect is particularly salient when comparing the variable range for change in injecting frequency (range: −42 to +54) versus change in total syringes acquired (range: −180 to +190). Extrapolating the regression results suggests that reducing injecting frequency by 10 episodes per fortnight would increase coverage by 110 percentage points, whilst providing PWID with another 10 syringes would only increase their coverage by 60 percentage points. The maximum injecting frequency of PWID over a fortnight is small compared with the number of syringes they can acquire, suggesting that interventions to reduce injecting frequency would have the greatest effect upon individual-level coverage.
Reducing injecting frequency carries additional benefits. High-frequency injecting has been associated with BBV infection, 16, 17 injection-related infection, 18 overdose 19 and other injecting-related risk. 20 High-frequency injecting has also been associated with insufficient coverage. 1, 3 Reducing injecting frequency via drug treatment, particularly via OST prescription is efficacious and cost-effective. 21 Furthermore, the association between OST prescription and higher coverage has been demonstrated in our previous work 5, 13 and in that of others. 4 For PWID who do not inject opiates (meaning OST prescription is inappropriate), other methods of reducing injecting frequency are needed. Some work has been done on medication-based replacement therapies for meth/amphetamine-dependent PWID 22, 23 with varying results. However, more work is needed to validate non-OST treatments.
The differential effect sizes we report do not mean we recommend one intervention over another. Maximizing coverage comes from a coordinated approach, whereby multiple methods of syringe delivery, both formal and informal, complement the idiosyncratic needs of PWID-a diverse population with different levels of service utilization. Whilst some interventions have greater impact than others, each helps ensure that PWID can acquire sufficient syringes when and where required. For example, increasing syringe acquisition via increased dispensation may prove more cost-effective and easier to implement (and would target all PWID, rather than only opioid injectors); however, we only highlight here the different impacts based upon the results of analysis. It must also be remembered that the behaviours observed in our sample may not correspond to behaviours of other PWID populations, as shown in Bluthenthal et al.'s findings. 1 The PWID in our sample inject less often than many other populations, 24, 25 which has an effect upon coverage. 1 Consequently, other PWID samples may not experience the effect sizes seen here.
Finally, our factor analysis supports the assertion that numerous behaviours/practices affect coverage, beyond the bipartite relationship between syringe acquisition and injecting frequency. A consistent method of measuring individual-level coverage is important for future research and evaluation. For example, McCormack et al. produced strong evidence for including a syringe stockpiling parameter (see Limitations). Of the parameters tested, 'instances of syringe acquisition' had least weight upon the latent factor; although excluded from our coverage formula, it was part of Bluthenthal et al.'s 1 original formula construction, and appears in other research. 3, 4 Our analysis suggests its omission is warranted.
Limitations of this study
Each parameter within the coverage formula is open to recall bias, which is compounded by each additional measure. We believe the 2-week period used in our analysis reduced the bias in recall.
McCormack et al.'s
6 finding that many Australian PWID stockpile syringes was published after construction of the MIX questionnaire, so stockpiling was not included in our coverage measure or analysis. However, in accordance with Bluthenthal et al.'s 1 finding that higher coverage reduces injecting risk, we hypothesized that PWID who stockpile syringes have the highest levels of coverage. If true, stockpiling has a large effect upon continuous coverage. We have since included stockpiling in a recent MIX questionnaire update, so can explore this hypothesis in future research.
Not all parameters in the coverage measure occur commensurately. For example, PWID may inject daily, yet only acquire syringes (and stockpile) monthly. Our 2-week time period may therefore miss some coverage behaviours. Future research should determine the most appropriate timeframe to capture infrequent behaviours, whilst minimizing recall bias.
Finally, 44% of all coverage responses were missing. Though most (71%) were due to injecting abstinence, invalid coverage parameter responses precluded analysis of otherwise valid data. Also, because we calculated change between succeeding interviews, missing data complicated analysis as it relied upon sequential ordering of valid coverage/parameter data, meaning many change outcomes were excluded.
Conclusions
Measurement of individual-level needle and syringe coverage is based on parameters corresponding to particular behaviours. Changes in these behaviours affect individuals' ability to 'cover' their injection episodes with sterile syringes. Our analysis suggests that decreased injecting frequency would improve coverage nearly twice as much as an equivalent increase in syringe acquisition. Improving the quantity and quality of NSP service delivery is vitally important to ongoing harm reduction efforts, but interventions to reduce injecting frequency (such as OST prescription) may have greater impact for particular PWID, notably primary opioid injectors. 
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